EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer

Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard Burris, Mohamed Bouattour und 17 weitere

Future Oncology · 2023

DOI: 10.2217/fon-2023-0468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Do-Youn Oh und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National Universi…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Biliary Tract Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WHAT IS THIS SUMMARY ABOUT?: This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy. WHAT WERE THE RESULTS OF THE STUDY?: Participants who took durvalumab and chemotherapy had a 20% lower chance of experiencing death at any point in the study compared with participants who received placebo and chemotherapy. The side effects experienced by participants were similar across treatment groups, and less than 12% of participants in either treatment group had to stop treatment due to treatment-related side effects. WHAT DO THE RESULTS OF THE STUDY MEAN?: Overall, these results support durvalumab and chemotherapy as a new treatment option for people with advanced BTCs. Based on the results of this study, durvalumab is now approved for the treatment of adults with advanced BTCs in combination with chemotherapy by government organizations in Europe, the United States and several other countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsBiliary Tract NeoplasmsAdultHumansAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineGemcitabineAntibodies, Monoclonal

Stichwörter der Autor:innen

bile duct cancerbiliary tract cancerchemotherapycholangiocarcinomacisplatindurvalumabgemcitabineimmunotherapylay summaryplain language summary

Substanzen

CisplatinDeoxycytidineGemcitabinedurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Division of Hematology & Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
  • Cancer Center of Nanjing, Jinling Hospital, Nanjing, China.
  • Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, & National Institute of Cancer Research, Tainan, & National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
  • Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover, Germany.

Zitieren

APA

Oh, D. Y., He, A. R., Qin, S., Chen, L. T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Lee, M. A., Kitano, M., Burris, H., Bouattour, M., Tanasanvimon, S., McNamara, M. G., Zaucha, R., Avallone, A., Tan, B., Cundom, J., Lee, C. K., …, & Valle, J. W. (2023). Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0468

Vancouver

Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer. Future Oncology. 2023. doi:10.2217/fon-2023-0468

BibTeX
@article{Oh2023,
  author = {Oh, Do-Youn and He, Aiwu Ruth and Qin, Shukui and Chen, Li-Tzong and Okusaka, Takuji and Vogel, Arndt and Kim, Jin Won and Suksombooncharoen, Thatthan and Lee, Myung Ah and Kitano, Masayuki and Burris, Howard and Bouattour, Mohamed and Tanasanvimon, Suebpong and McNamara, Mairead G and Zaucha, Renata and Avallone, Antonio and Tan, Benjamin and Cundom, Juan and Lee, Choong-Kun and Takahashi, Hidenori and Ikeda, Masafumi and Chen, Jen-Shi and Wang, Julie and Makowsky, Mallory and Rokutanda, Nana and Żotkiewicz, Magdalena and Kurland, John F and Cohen, Gordon and Valle, Juan W},
  title = {Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2023-0468}
}
Kostenlos starten →